NEUMORA THERAPEUTICS, INC. Shareholders' Equity
NEUMORA THERAPEUTICS, INC. (NMRA) had Shareholders' Equity of $44.52 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity Attributable to Parent $44.52M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $70.68M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $103.87M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $132.16M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $44.52M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $70.68M 10-Q · filed 2026-08-14 |
| 2025-12-31 | $103.87M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $132.16M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $182.88M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $228.36M 10-Q · filed 2026-08-14 |
| 2024-12-31 | $287.06M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $320.74M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $381.26M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $424.54M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $469.08M 10-K · filed 2026-03-30 |
| 2023-09-30 | $512.69M 10-Q · filed 2024-11-12 |
| 2023-06-30 | -$513.54M 10-Q · filed 2024-11-12 |
| 2023-03-31 | -$477.92M 10-Q · filed 2024-11-12 |
| 2022-12-31 | -$446.85M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$422.00M 10-Q · filed 2023-11-01 |
| 2022-06-30 | -$394.71M 10-Q · filed 2023-11-01 |
| 2022-03-31 | -$366.02M 10-Q · filed 2023-11-01 |
| 2021-12-31 | -$325.22M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |